- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06828159
Dietary Wild Blueberries and Joint Health
November 3, 2025 updated by: Arpita Basu, University of Nevada, Las Vegas
Effects of Dietary Wild Blueberries on Gut Health and Inflammation and Joint Pain
The goal of this proposed study is to examine the effects of dietary wild blueberries on gut microbiome, serum markers of inflammation, and joint function in adults.
Each participant will consume 25g freeze-dried blueberries or matched placebo powder for 12 weeks, with a 2-week washout phase between.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arpita Basu
- Phone Number: 702-895-4576
- Email: arpita.basu@unlv.edu
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- OMRF
-
Contact:
- Judy Goodman
- Phone Number: 405- 271-3007
- Email: judy-goodman@omrf.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults with documented multi-joint/knee arthritis
Exclusion Criteria:
- inability to give informed consent
- pregnancy or lactation
- planned knee replacement surgery
- allergy or contraindication to berries
- recent trauma of the knee responsible of the symptomatic knee
- intra-articular injection in the target knee/hip in the last 3 months
- oral corticosteroid therapy ≥ 5 mg/day (prednisone equivalent) at baseline
- use of berry extracts in the last 3 months
- special diets
- cancer treatment
- bone diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Wild blueberries
25g freeze-dried wild blueberries daily for 12 weeks
|
Freeze-dried wild blueberry powder 25g/day
|
|
Placebo Comparator: Placebo
Placebo powder free from polyphenols matched for calories
|
Placebo powder matched for calories and no polyphenols
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum biomarkers of joint function
Time Frame: 12 weeks
|
Serum biomarkers of inflammation and cartilage degradation will be measured in the wild blueberry and placebo groups and compared for outcomes.
Pain scores will also be measured using self-reported questionnaires.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Gut microbiome
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
March 1, 2028
Study Registration Dates
First Submitted
February 10, 2025
First Submitted That Met QC Criteria
February 10, 2025
First Posted (Actual)
February 14, 2025
Study Record Updates
Last Update Posted (Estimated)
November 5, 2025
Last Update Submitted That Met QC Criteria
November 3, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMRF WB01
- WBANA01 (Other Grant/Funding Number: WBANA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Joint Pain
-
SI-BONE, Inc.Active, not recruitingSacroiliac Joint Pain | Sacroiliac Joint DysfunctionUnited States
-
Christoph Maier, Prof. Dr.CompletedLow Back Pain | Facet Joint PainGermany
-
Tri-Service General HospitalNot yet recruitingSacroiliac Joint Pain | Sacroiliac Joint Dysfunction
-
Assiut UniversityCompletedLumbar Facet Joint PainEgypt
-
Shanghai Changzheng HospitalCompletedFacet Joints; Degeneration ; Deep Learning ;Artificial Intelligence | Facet Joint Pain; Low Back Pain | Facet Joint DiseaseChina
-
Samar Mimi Mohamed OkbyNot yet recruitingSacroiliac Joint Pain
-
Cairo UniversityCompletedSacroiliac Joint PainEgypt
-
Avanos MedicalCompletedSacroiliac Joint PainUnited States
-
Johns Hopkins UniversityMilton S. Hershey Medical Center; United States Naval Medical Center, San Diego and other collaboratorsCompletedSacroiliac Joint PainUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of